The WHO estimates that 422 million people worldwide suffer from diabetes, with the majority residing in low- or middle-income ...

Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with ... insulin pumps, pump supplies, and ...

An early-morning rise in blood sugar is common in people with diabetes. Find out more about why it happens and how to prevent ...

People with type 1 diabetes require continuous insulin treatment and must regularly measure their glucose levels. With open-loop therapies*, insulin administration is manually controlled ...

Tandem is following competitor Insulet’s lead with the second automated insulin delivery system indicated for Type 2 diabetes ...

Insulet reported a higher-than-expected profit in the fourth quarter on Thursday, driven by strong demand for its wearable insulin pumps.

Arti Masturzo, M.D., chief medical officer of CCS, spoke with MHE in this third part of a video series to share how CCS helps ...

Why understanding the differences between Type 1 and Type 2 diabetes is essential for better health management and effective ...

slim X2 and Mobi insulin pumps, was already approved for people with type 1 diabetes aged 2 years or older. The new indication is for people with T2D aged 18 years or older. The pumps are approved ...

Control-IQ+, already cleared for use by people with type 1 diabetes ... and alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on ...

Pharmac is seeking public feedback on a proposal to fund a new, additional type of insulin for people with diabetes from 1 May 2025. The new medicine (branded as Ryzodeg) is a combination of two ...

Tandem Diabetes Care, Inc.’s TNDM fourth-quarter 2024 performance was driven by its impressive range of new products. The company’s impressive strategic initiatives provide a favorable opportunity for ...